{
    "nct_id": "NCT06859762",
    "official_title": "A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL217 in Patients with Advanced Solid Tumors",
    "inclusion_criteria": "* Informed of the study before the start of the study and voluntarily sign their name and date in the informed consent form (ICF)\n* Able and willing to comply with protocol visits and procedures\n* Aged ≥ 18 years\n* Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1\n* Tumor types as below:\n\nFor Part 1 and Part 2: Pathologically confirmed diagnosis of an advanced solid tumor, including adenocarcinoma and neuroendocrine neoplasm in gastrointestinal (GI), esophagus, gastroesophageal junction, pancreas or ampulla, and other solid tumors.\n\nFor Part 3 (Histologically or cytologically confirmed diagnosis+ locally advanced unresectable or metastatic disease):CohortA（colorectal adenocarcinoma）: Have clear documentation of rat sarcoma (RAS), vrafmurine sarcoma viral oncogene homolog B (BRAF), and microsatellite instability/mismatch repair status. Participants must have received at least one line of prior cytotoxic chemotherapeutic regimen. CohortB（ Human Epidermal Growth Factor Receptor 2 （HER2）-negative gastric, esophageal or gastroesophageal junction adenocarcinoma）: Participants must have received at least one line of prior cytotoxic chemotherapeutic regimen. CohortC(pancreatic adenocarcinoma): Participants must have received at least one line of prior cytotoxic chemotherapeutic regimen. CohortD(other advanced solid tumors)\n\n* Adequate organ and bone marrow function.\n* Have at least 1 extracranial measurable tumor lesion.\n* Adequate archival formalin-fixed paraffin embedded （FFPE） tissue from prior biopsy.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with an agent targeting CDH17\n* Prior discontinuation of a topoisomerase I inhibitor due to treatment-related toxicities.\n* Have received a topoisomerase I inhibitor within 6 months before the first dose of study drug.\n* Have received an ADC consisting of a topoisomerase I inhibitor.\n* Concurrent enrollment in another clinical study, unless it is an observational clinical study.\n* Inadequate washout period for prior anticancer treatment before the first dose of study drug\n* Undergone major surgery within 4 weeks before the first dose of study drug or expect major surgery during the study.\n* Received long term systemic steroids or other immunosuppressive therapy within 2 weeks before the first dose of study drug.\n* Received any live vaccine within 4 weeks before the first dose of study drug or intend to receive a live vaccine during the study.\n* Diagnosis or evidence of spinal cord compression or leptomeningeal carcinomatosis.\n* Uncontrolled or clinically significant cardiovascular and cerebrovascular diseases.\n* A history of non-infectious interstitial lung disease (ILD)/pneumonitis that requires steroids, current active ILD/pneumonitis.\n* Have clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses.\n* Uncontrolled third-space fluid that requires repeated drainage.\n* Digestive system disease that may cause bleeding, perforation, jaundice, gastrointestinal obstruction.\n* An active tuberculosis based on medical history.\n* Known human immunodeficiency virus (HIV) infection.\n* Active hepatitis C infection.",
    "miscellaneous_criteria": ""
}